UNSPSC 41202028: Gonococcal antibody test (gat)

In this classification, Gonococcal antibody test (gat) are devices used in test to identify specific Gonococcal antibody test (gat) antibodies in serum. US FDA regulates Gonococcal antibody test (gat) under 21 CFR 866.3290 and under FDA product code LGB.

UNSPSC 41202028 Gonococcal antibody test (GAT) is a Commodity code capturing laboratory diagnostic testing supplies and services for sexually transmitted infection (STI) detection, where state and local governments procure reagents, test kits, analyzers, collection supplies, and related testing services to support public health STI screening programs. Recent opportunities reflect procurement of gonococcal and chlamydial nucleic acid amplification test (NAAT) kits, HIV and syphilis testing reagents, specimen collection supplies, and comprehensive laboratory testing services from public health agencies, county health departments, and correctional supervision departments. The issuing-body mix spans state health departments (Illinois Department of Public Health), county health services (Collin County Health Care Services), county corrections departments (Collin County Community Supervision and Corrections Department), county boards (Gwinnett County, Georgia), and municipal public health programs (City of Austin). Illinois Department of Public Health appears as a repeat buyer, issuing change orders and emergency procurements for Abbott HIV/syphilis reagents and Hologic NG/NT testing kits to support statewide STI testing operations.

Recent activity concentrates in Texas, Illinois, and Georgia. Representative recent opportunities include the Illinois Department of Public Health change order for Hologic NG/NT testing and kits (IFB, response due October 13, 2026) increasing annual testing from 15,000 to 25,000 tests and collection kits from 15,000 to 30,000 units with a revised contract cost of $900,000 over five years; Collin County Community Supervision and Corrections Department RFP for offender specimen collection and drug testing services (RFP 2026-327, response due July 23, 2026) covering approximately 25,031 annual tests at an estimated contract value of $600,000; the City of Austin reissued IFB for rapid HIV Type 1 and Type 2 test kits (IFB 9100 AAM1023 REBID, response due September 3, 2026) at an estimated annual volume of 375 test kits and 79 control kits; and Illinois Department of Public Health emergency procurement of Abbott HIV and syphilis testing reagents and maintenance services ($38,079.50, awarded to Abbott Laboratories as sole source). Contracts typically run one to five years with performance specifications covering CLIA certification, turnaround times, electronic result reporting, and quality control documentation; pricing structures often employ per-test or per-kit unit rates with freight and staffing included.